ArticleOncoimmunology2013
A road less traveled paved by IDO silencing: Harnessing the antitumor activity of neutrophils.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment.Frontiers in oncology · 2023Review
- Tumor-Mediated Neutrophil Polarization and Therapeutic Implications.International journal of molecular sciences · 2022Review
- Review
- Immunomodulatory Effects of Genetic Alterations Affecting the Kynurenine Pathway.Frontiers in immunology · 2019Review
- Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.Frontiers in immunology · 2018Review
- The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy.Frontiers in immunology · 2018Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.Cancer research · 2014Article
- Trial watch: IDO inhibitors in cancer therapy.Oncoimmunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orchestrating a cytotoxic polymorphonuclear neutrophil (PMN) response strictly focused within the tumor tissue remains a formidable challenge for the successful therapeutic use of these cells. A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.